Javascript must be enabled to continue!
EGFR Mutation and FHIT Methylation: Inverse Relationship in Patients with Lung Adenocarcinoma and Tuberculosis
View through CrossRef
Objective: To investigate the genetic correlations between epithelial growth factor receptor (EGFR) mutation and FHIT methylation in patients diagnosed with lung adenocarcinoma (AC) and pulmonary tuberculosis (TB). Methods: The presence of EGFR mutations and the methylation status of the FHIT gene in patients presenting with AC and TB were analyzed. The correlation between TB status and the observed genetic and epigenetic variations was also examined. Results: Among the 90 patients included in the study, 38 exhibited EGFR mutations (14 among those with TB and 24 among those without TB), while 29 exhibited FHIT myelination (19 among those with TB and 10 among those without TB). Furthermore, the protein expression levels of EGFR and FHIT were significantly higher in patients diagnosed solely with AC compared to those presenting with both AC and TB. A robust inverse correlation was identified between TB status and the frequency of EGFR mutation (P < 0.001). Moreover, significant associations were observed between TB status and FHIT methylation (P < 0.01). Conclusion: The findings suggest a correlation between TB and the prevalence of EGFR mutation and FHIT methylation in the pathogenesis of AC.
Bio-Byword Scientific Publishing, Pty. Ltd.
Title: EGFR Mutation and FHIT Methylation: Inverse Relationship in Patients with Lung Adenocarcinoma and Tuberculosis
Description:
Objective: To investigate the genetic correlations between epithelial growth factor receptor (EGFR) mutation and FHIT methylation in patients diagnosed with lung adenocarcinoma (AC) and pulmonary tuberculosis (TB).
Methods: The presence of EGFR mutations and the methylation status of the FHIT gene in patients presenting with AC and TB were analyzed.
The correlation between TB status and the observed genetic and epigenetic variations was also examined.
Results: Among the 90 patients included in the study, 38 exhibited EGFR mutations (14 among those with TB and 24 among those without TB), while 29 exhibited FHIT myelination (19 among those with TB and 10 among those without TB).
Furthermore, the protein expression levels of EGFR and FHIT were significantly higher in patients diagnosed solely with AC compared to those presenting with both AC and TB.
A robust inverse correlation was identified between TB status and the frequency of EGFR mutation (P < 0.
001).
Moreover, significant associations were observed between TB status and FHIT methylation (P < 0.
01).
Conclusion: The findings suggest a correlation between TB and the prevalence of EGFR mutation and FHIT methylation in the pathogenesis of AC.
Related Results
Abstract 1769: The clinical outcome of stage I lung adenocarcinoma patients with or without activating EGFR mutation
Abstract 1769: The clinical outcome of stage I lung adenocarcinoma patients with or without activating EGFR mutation
Abstract
Purpose: Advanced stage lung adenocarcinoma patients with activating EGFR mutation have better survival result after EGFR tyrosine kinase inhibitor develope...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Abstract
EGFR is an attractive target for the treatment of a variety of solid tumors because of its role as a driver oncogene and high level of expression. Four EGFR...
Abstract 2205: Identification of potential biomarker related to EGFR mutation by functional proteome profiling in primary non-small cell lung cancer
Abstract 2205: Identification of potential biomarker related to EGFR mutation by functional proteome profiling in primary non-small cell lung cancer
Abstract
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers which the leading cause of cancer-related death worldwide. Recently, epide...
The Relationship Between Risk Factors And Egfr Mutation In Lung Adenocarcinoma Patients
The Relationship Between Risk Factors And Egfr Mutation In Lung Adenocarcinoma Patients
Several clinical characteristics are associated with a high frequency of EGFR mutation activation. The prevalence of EGFR mutation in different clinical characteristic subgroups ca...
Abstract 1819: Acquired T790M mutation after first generation EGFR tyrosine kinase retreatment
Abstract 1819: Acquired T790M mutation after first generation EGFR tyrosine kinase retreatment
Abstract
Introduction The first or second generation EGFR TKI drugs showed good overall response and progression free survival rates in EGFR mutation positive patien...
Clinical and genetic characteristics of EGFR-mutant lung adenocarcinoma transformed SCLC.
Clinical and genetic characteristics of EGFR-mutant lung adenocarcinoma transformed SCLC.
e20588 Background: Transformation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is one of the resistance mechanism of EGFR tyrosine kinase inhibitors. H...
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
8563 Background: There are limited reports on biomarker studies of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon...

